Charlottesville, VA (8 September 2009) : Biovista announced today that it will present at the Marcus Evans 2nd Annual Drug Repositioning and Pipeline Enhancement conference in Philadelphia, PA, Sept. 17-18, 2009. The presentation will cover the advantages of repositioning as a component of portfolio development and lifecycle management, with specific Biovista drug case studies in … Read More
Author: Vassilis Virvilis
Biovista sponsors the 2009 Notch Meeting
Athens, GR, September 2nd, 2009 — Biovista Inc. is pleased to announce its sponsoring of the international 2009 Notch Meeting to be held in Athens, Greece, from September 27th to October 1st, 2009. The Notch Meeting is a biennial event on general Notch research that aims to reflect the diversity of Notch research and bring together researchers … Read More
Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy
CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More
Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis
CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More
Biovista delivers critical data for the CTSA Pharmaceutical Assets Portal
Charlottesville, VA, 12 February 2009 In recent years the life sciences community is seeing increasing evidence showing that drugs that have failed as a cure for one disease may hold promise for a different condition. An academic consortium led by UC Davis is now leading a collaborative effort, called the Pharmaceutical Assets Portal, to allow … Read More